Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2008

Filing Date
Filed February 27, 2009
Period End
December 31, 2008
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed February 27, 2009. Cited figures are marked; the original filing is the authoritative source.

This 10-K, filed February 27, 2009, is from Schering-Plough Corporation (NYSE: SGP), not Merck & Co. (MRK).

Schering-Plough and Merck operate the cholesterol franchise (VYTORIN and ZETIA) through an equity-method joint venture, so those products' sales are not in Schering-Plough's reported net sales. The filing covers fiscal 2008, a year of transformation. Net sales rose 46% to $18.5 billiona, driven largely by the November 2007 acquisition of Organon BioSciences (OBS), which contributed $5.4 billion.

Net income available to common shareholders was $1.75 billionb, or $1.07 per diluted share, helped by a $160 million gain on divested Animal Health products and $1.9 billion of equity income from the cholesterol joint venture. Operating cash flow was $3.4 billion, and net debt fell to $4.8 billion from $7.1 billion. The main investor concern is the cholesterol franchise.

Global VYTORIN and ZETIA sales fell 11% in 2008, and U.S. sales fell 24%, after the ENHANCE trial results (January 2008) and the SEAS trial (July 2008) drew heavy media attention, congressional and state investigations, and securities and consumer class actions. Management expects 2009 U.S. cholesterol sales to be lower than 2008, while international sales should keep growing. Management also reported a Productivity Transformation Program targeting $1.5 billionc of annualized savings by 2012, with about $1.25 billion by end-2010, and R&D spending of $3.5 billion, which it expects to grow in the mid-single digits in 2009.

Growth now rests on a broader base: REMICADE (international sales of $2.1 billiond, up 28%), TEMODAR, NASONEX, and the newly acquired women's health and central nervous system products. Offsetting risks include loss of exclusivity for several products, competitive and pricing pressure in the U.S., and an expanding litigation and regulatory agenda. Schering-Plough's Moody's, S&P and Fitch ratings are investment grade (Baa1, A-, BBB+), with outlooks revised to stable.

Key Highlights

  1. Net sales of $18.5 billion in 2008, up 46% from $12.7 billion, with OBS contributing $5.4 billion; about 70% of sales were outside the U.S.
  2. Net income available to common shareholders of $1.75 billion ($1.07 diluted EPS), versus a $1.59 billion loss in 2007 that included a $3.8 billion acquired in-process R&D charge.
  3. Cholesterol joint venture with Merck: VYTORIN and ZETIA global sales down 11% and U.S. sales down 24%, with U.S. prescription share falling from 16.9% to 10.1%; equity income was $1.87 billion.
  4. Productivity Transformation Program targets $1.5 billion in annualized savings by 2012 (about $1.25 billion by end-2010), including OBS integration synergies; 2008 special charges were $329 million.
  5. Operating cash flow of $3.4 billion; net debt reduced to $4.8 billion from $7.1 billion, with $929 million of long-term debt repaid, including early repayment of €600 million of term loan.
  6. R&D spending of $3.5 billion (about 19% of net sales), with 12 late-stage projects; management expects 2009 R&D to grow in the mid-single digits.
  7. Material legal exposure: ENHANCE and SEAS-related securities, consumer fraud, ERISA and state/federal investigations; a federal securities settlement was preliminarily approved in February 2009 with final approval hearing set for June 1, 2009.

Financial Statements

FY2008 against FY2007

Line itemFY2008FY2007Change
Revenue$23.85B$24.20B−1.4%
Cost of Revenue$5.58B$6.14B−9.1%
Gross Profit$18.27B$18.06B+1.2%
R&D Expenses$4.80B$4.88B−1.6%
SG&A Expenses$7.38B$7.56B−2.4%
Interest Expense$251.00M——
Net Income$7.81B$3.28B+138.4%
EPS (Basic)$3.65$1.51+141.7%
EPS (Diluted)$3.63$1.49+143.6%
Shares Outstanding (Basic)2.14B——
Shares Outstanding (Diluted)2.14B——

Frequently Asked Questions

  1. Why did Schering-Plough's reported sales rise so sharply in 2008?

    The increase was mainly due to the November 19, 2007 acquisition of Organon BioSciences, which added $5.4 billion of 2008 net sales, including $1.9 billion from Intervet (Animal Health). Excluding OBS, sales growth was more modest, supported by REMICADE, TEMODAR and NASONEX.

  2. How much have VYTORIN and ZETIA hurt the company, and what is the 2009 outlook?

    The cholesterol franchise's sales are not in Schering-Plough's net sales, but its share of joint venture profits (equity income) fell from $2.05 billion in 2007 to $1.87 billion in 2008. Management expects 2009 U.S. sales of VYTORIN and ZETIA to be lower than in 2008, while international sales excluding currency effects should keep growing. Management says it cannot predict the long-term performance of this franchise.

  3. What is the Productivity Transformation Program and how much will it save?

    Announced in April 2008, the program targets $1.5 billion of annualized savings by 2012, with about $1.25 billion expected by the end of 2010. It includes OBS integration synergies and involves plant network reduction. In 2008 it generated $329 million of special and acquisition-related charges, mostly employee termination costs.

  4. Is the company's balance sheet and debt position manageable?

    Net debt fell to $4.8 billion at year-end 2008 from $7.1 billion, and operating cash flow was $3.4 billion. Long-term debt was $7.9 billion, and the company had a $2.0 billion revolving credit facility. Credit ratings were Baa1 (Moody's), A- (S&P) and BBB+ (Fitch), with outlooks revised to stable in 2008 and early 2009. Management said it has no current plans to access equity or debt markets.